indias-wockhardt-in-fifth-european-acquisition

India's Wockhardt in fifth European acquisition

The Indian pharmaceutical company spends $265 million to acquire Negma Laboratories, a French research-based major with 172 patents.
Indian pharmaceutical and biotechnology company, Wockhardt, is to buy Negma Laboratories of France in an all-cash deal for $265 million that marks its fifth acquisition in Europe.

Negma is the fourth-largest independent integrated pharmaceutical group in France. For the most recent fiscal year it had sales of $150 million. Negma is a research-based company with 172 patents and leading positions in the osteoarthritisrheumatology, phlebotonic and the arterial hypertension segments. Wockhardt intends to use the patents to extend its business to other European markets.

At the agreed price of $265 million, Negma is valued at 1.8 times sales and 9.7 times Ebitda.

The acquisition makes Wockhardt the largest Indian pharmaceutical company in Europe with more...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222